Altimmune, Inc. (NASDAQ:ALT) Stock Has Consensus Price Target of $14.33 According to Analysts

Shares of Altimmune, Inc. (NASDAQ:ALT) have been assigned a consensus recommendation of “Moderate Buy” from the ten analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $14.33.

A number of brokerages recently weighed in on ALT. Wall Street Zen raised Altimmune from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a research note on Monday, September 21st. HC Wainwright reiterated a “buy” rating on shares of Altimmune in a research report on Tuesday, July 28th. Leerink Partners assumed coverage on shares of Altimmune in a research report on Monday, June 22nd. They set an “outperform” rating and a $10.00 price target for the company. Finally, Evercore reissued an “outperform” rating on shares of Altimmune in a research note on Wednesday, September 23rd.

Altimmune Price Performance

Shares of NASDAQ:ALT opened at $2.97 on Friday. The company’s fifty day moving average price is $3.10 and its 200-day moving average price is $3.06. The company has a debt-to-equity ratio of 0.07, a current ratio of 26.78 and a quick ratio of 26.78. The firm has a market capitalization of $577.72 million, a price-to-earnings ratio of -3.81 and a beta of 0.18. Altimmune has a one year low of $2.56 and a one year high of $6.44.

Altimmune (NASDAQ:ALT) last released its earnings results on Wednesday, August 12th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. Altimmune had a negative return on equity of 31.41% and a negative net margin of 214,860.98%. On average, equities research analysts anticipate that Altimmune will post -0.58 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP lifted its stake in Altimmune by 268.7% in the first quarter. Dimensional Fund Advisors LP now owns 1,045,926 shares of the company’s stock worth $3,221,000 after acquiring an additional 762,223 shares during the period. Bank of America Corp DE boosted its position in Altimmune by 48.6% during the 1st quarter. Bank of America Corp DE now owns 570,203 shares of the company’s stock valued at $1,756,000 after acquiring an additional 186,420 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Altimmune during the 2nd quarter worth approximately $2,097,000. Squarepoint Ops LLC raised its position in shares of Altimmune by 1,016.5% in the 2nd quarter. Squarepoint Ops LLC now owns 202,380 shares of the company’s stock worth $615,000 after acquiring an additional 184,254 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. lifted its stake in shares of Altimmune by 156.5% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 518,198 shares of the company’s stock valued at $1,575,000 after purchasing an additional 316,209 shares during the period. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biotechnology company focused on developing treatments for obesity and liver diseases. The company’s lead product candidate is pemvidutide, a dual GLP-1/glucagon receptor agonist being studied for chronic weight management and metabolic dysfunction-associated steatohepatitis (MASH), a form of liver disease associated with metabolic disorders.

Altimmune’s research programs are designed to address diseases with significant unmet medical needs, including obesity-related complications and conditions involving liver inflammation and fibrosis.